Nitroglycerin topical - Covis Pharma/MediQuest
Alternative Names: MQX-503; VascanaLatest Information Update: 02 Oct 2021
At a glance
- Originator MediQuest Therapeutics
- Developer Covis Pharma; MediQuest Therapeutics
- Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
- Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Raynaud's disease
Most Recent Events
- 26 Aug 2020 Discontinued - Phase-III for Raynaud's disease in USA (Topical) (Covis Pharma website, August 2020)
- 26 Sep 2017 Discontinued - Phase-III for Raynaud's disease in Canada (Topical,gel)
- 26 Sep 2017 Discontinued - Phase-III for Raynaud's disease in European Union (Topical,gel)